The pharmaceutical companies Pfizer and BioNTech They have assured this Monday in a statement that the COVID-19 vaccine they jointly develop is safe for children between the ages of 5 and 11. The companies plan to send the data collected from their latest clinical trials to the US Food and Drug Administration (FDA) for emergency authorization in the US before the end of the month.
FDA experts recommend the third dose of Pfizer for the elderly but reject it for the general population
As indicated to the agency Associated Press Pfizer Vice President Bill Gruber used a third of the amount that is routinely administered in a puncture in the trials for this age group. Even so, he added, the levels of antibodies generated in these children are as strong as those of adolescents and adults after receiving the vaccine.
So far, the vaccine from the American company and its German partner has been approved by both the FDA, the European Medicines Agency (EMA) or the World Health Organization (WHO) for everyone over 12 years. However, with the start of the school year in the northern hemisphere, the company began developing clinical trials in younger age groups. If approved by the FDA, it would become the first vaccine suitable for children under 12 in the United States.